Sharekhan

Piramal Pharma Ltd

Fri 8/05/2026,16:3:19 NSE: PPLPHARMA

₹ 179.85 -3.88 (-2.11%)
BUY NOW Buy Piramal Pharma Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Piramal Pharma Ltd

Fri 8/05/2026,16:1:0

Piramal Pharma Ltd

Fri 8/05/2026,16:3:19 | NSE : PPLPHARMA

₹ 179.85-3.88 (-2.11%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 183.50

Previous Close

₹ 183.73

Volume

6184773

Mkt Cap ( Rs. Cr)

₹23906.53

High

₹ 185.47

Low

₹ 178.30

52 Week High

₹ 226.00

52 Week Low

₹ 132.30

Book Value Per Share

₹ 59.67

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Piramal Pharma Ltd

Your Vote -

Buy

64.37%

Hold

11.88%

Sell

23.75%

64.37%

261 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

179.85

1329

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

1329

Option Chain

Analyzes market sentiment, predicts Piramal Pharma Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    4 May 2026, 3:22PM Intimation of Schedule of Analyst/ Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    4 May 2026, 3:16PM Intimation of Schedule of Analyst/ Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    30 Apr 2026, 2:46PM Transcript of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2026

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    30 Apr 2026, 2:53PM Transcript of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2026

  • Piramal Pharma - General Updates

    29 Apr 2026, 4:51PM Contact details of Key Managerial Personnel as required under Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulatio

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    29 Apr 2026, 4:45PM Audio Recording of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2026

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    29 Apr 2026, 4:33PM Audio Recording of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2026

  • Piramal Pharma - Contact Details Of Key Managerial Personnel As Required Under Regulation 30(5) Of The SEBI (Listing Obligati

    29 Apr 2026, 5:00PM Please refer attached file

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    29 Apr 2026, 4:52PM Audio Recording of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2026

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Change in Registered Office Address

    28 Apr 2026, 9:40PM Please refer attached

  • Piramal Pharma - Appointment of Company Secretary and Compliance Officer

    28 Apr 2026, 9:38PM Please refer attached details of appointment of Company Secretary and Compliance Officer

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Cessation

    28 Apr 2026, 9:37PM Please refer attached details of cessation of Interim Company Secretary and Compliance Officer

  • Piramal Pharma - Results - Financial Year Ended March 31, 2026

    28 Apr 2026, 9:33PM Please refer attached

  • Piramal Pharma Q4 net profit down 5.64% at Rs 261.63 cr

    28 Apr 2026, 9:30PM The company reported standalone net profit of Rs 261.63 crore for the quarter ended March 31, 2026 as compared to Rs 277.27 crore in the same period l

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    28 Apr 2026, 9:29PM Please refer attached.

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Investor Presentation

    28 Apr 2026, 9:27PM Please refer attached.

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Change in Directorate

    28 Apr 2026, 9:25PM Please refer attached details of change in directorate.

  • Piramal Pharma - Address Change

    28 Apr 2026, 9:25PM Piramal Pharma Limited has informed the Exchange regarding change in Registered Office of the company.

  • Piramal Pharma - Change in Director(s)

    28 Apr 2026, 9:24PM Piramal Pharma Limited has informed the Exchange regarding Change in Director(s) of the company.

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Change in Management

    28 Apr 2026, 9:24PM Please refer attached details of change in management.

  • Piramal Pharma - Change in Company Secretary/Compliance Officer

    28 Apr 2026, 9:23PM Piramal Pharma Limited has informed the Exchange about Change in Company Secretary/Compliance Officer

  • Piramal Pharma - Appointment

    28 Apr 2026, 9:21PM Piramal Pharma Limited has informed the Exchange regarding Appointment of Mr. Maneesh Sharma as Company Secretary & Compliance Officer of the company

  • Piramal Pharma - Investor Presentation

    28 Apr 2026, 9:19PM Piramal Pharma Limited has informed the Exchange about Investor Presentation

  • Piramal Pharma - Press Release

    28 Apr 2026, 9:17PM Piramal Pharma Limited has informed the Exchange regarding a press release dated April 28, 2026, titled ""Piramal Pharma Limited Announces Results for

  • Piramal Pharma - Cessation

    28 Apr 2026, 9:16PM Piramal Pharma Limited has informed the Exchange regarding Cessation of Ms. Pratibha Mishra as Company Secretary & Compliance Officer of the company

  • Piramal Pharma - Outcome of Board Meeting

    28 Apr 2026, 9:12PM Piramal Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on April 28, 2026.

  • Piramal Pharma - Outcome of Board Meeting

    28 Apr 2026, 9:10PM Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

  • Piramal Pharma - Board Meeting Outcome for Outcome Of The Board Meeting Dated April 28, 2026

    28 Apr 2026, 9:09PM Please find enclosed outcome of the Board Meeting held on April 28, 2026

  • Piramal Pharma has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026

    20 Apr 2026, 12:50PM As of March 2026, 34.85% is owned by Indian Promoters, 64.81% by Public and 0.34% by Non Promoters-Non Public. <p align=justify> Institutional holds 4

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    17 Apr 2026, 2:32PM Piramal Pharma Limited has informed the Exchange about Schedule of meet

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    17 Apr 2026, 2:21PM Pursuant to Regulation 30(6) of the SEBI Listing Regulations, please find enclosed herewith the details of the Conference Call with investors/analysts

  • Piramal Pharma - Board Meeting Intimation for Considering And Approving The Audited Financial Results (Standalone And Consoli

    17 Apr 2026, 2:17PM Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/04/2026 ,inter alia, to consider and a

  • Piramal Pharma - General Updates

    13 Apr 2026, 10:24AM Successful closure of US FDA Inspection at Piramal Pharma s manufacturing facility located at Lexington, USA

  • Piramal Pharma - Successful Closure Of US FDA Inspection At Piramal Pharma'S Manufacturing Facility Located At Lexington, USA

    13 Apr 2026, 10:20AM Please refer attached file

  • Piramal Pharma - General Updates

    6 Apr 2026, 6:32PM Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ESG Rat

  • Piramal Pharma - Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure

    6 Apr 2026, 6:26PM Please refer attached file

  • Piramal Pharma - General Updates

    1 Apr 2026, 4:26PM Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Comple

  • Piramal Pharma - Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure

    1 Apr 2026, 4:23PM Please refer attached file

  • Piramal Pharma - General Updates

    20 Mar 2026, 8:29PM Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ESG Rat

  • Piramal Pharma - Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure

    20 Mar 2026, 8:25PM Please refer attached file

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    2 Mar 2026, 3:27PM Piramal Pharma Limited has informed the Exchange about Schedule of Analyst/Investor meet

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    2 Mar 2026, 3:20PM Please refer attached file.

  • Piramal Pharma - General Updates

    24 Feb 2026, 5:07PM Contact details of Key Managerial Personnel as required under Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulatio

  • Piramal Pharma - Contact Details Of Key Managerial Personnel As Required Under Regulation 30(5) Of The SEBI (Listing Obligati

    24 Feb 2026, 5:04PM Please refer attached file

  • Piramal Pharma - Action(s) taken or orders passed

    14 Feb 2026, 1:10PM Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Revocation of closure direction for C

  • Piramal Pharma - General Updates

    14 Feb 2026, 12:58PM Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 FDA inspection

  • Piramal Pharma - Action(s) taken or orders passed

    11 Feb 2026, 6:43PM Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Piramal Pharma

    21 Mar 2025 , 10:19AM Piramal Pharma arm gets market authorization for Neoatrico from United Kingdom’s Medicines and Healthcare Products Regulatory Agency. Neoatrico is a paediatric solution used in treatment for hypotension in neonates, infants, and children. Positive

  • Piramal Pharma

    19 Feb 2025 , 10:26AM Piramal Pharma: The US FDA issued Form 483 with six observations for the company’s Turbhe facility.

  • Piramal Pharma

    23 Jan 2025 , 9:39AM Piramal Critical Care launches Chlorpromazine Hydrochloride in US. With this launch, company continues to expand their generic injectables portfolio.

  • Piramal Pharma

    18 Apr 2024 , 11:50AM The US FDA had Inspected Piramal Pharma’s manufacturing facility located at Riverview, USA and has issued an Establishment Inspection Report (EIR) for the said manufacturing facility and the inspection has now been successfully closed by the US FDA. Positive

  • Piramal Pharma

    26 Feb 2024 , 12:37PM The US FDA conducted a Pre-Approval Inspection (PAI) inspection of Piramal Pharma Limited's Lexington (USA) facility from 20th February, 2024 to 23rd February, 2024 for one of the product expected to be manufactured at this facility. On conclusion of the inspection, a Form-483 was issued with 2 observations. The observations does not pose any risk to site’s compliance standards or its business continuity. The Company is preparing a detailed response to said observations, which will be submitted to the US FDA within stipulated timelines. (Positive).

  • Piramal Pharma

    17 Jan 2024 , 9:37AM Piramal Critical Care division has announced the launch of a new 10mg/10mL (1 mg/mL) concentration of Zinc Sulfate for Injection USP in the United States of America. The launch will enable PCC to further expand their zinc sulphate existing product line and overall generic injectable portfolio. Positive
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Piramal Pharma Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 8851.02 8674.47 7863.96 6889.07 6168.87
Liabilities 8851.02 8674.47 7863.96 6889.07 6168.87
Equity 1327.16 1324.35 1322.95 1193.32 1185.91
Gross Profit 642 1040.44 617.92 97.53 397.3
Net Profit 700.01 691.4 391.22 69.5 343.05
Cash From Operating Activities 1328.12 548.77 358.29 71.52 255.2
NPM(%) 14.63 13.08 8.91 2.01 11.08
Revenue 4782.01 5285.71 4390.11 3443.22 3094.95
Expenses 4140.01 4245.27 3772.19 3345.69 2697.65
ROE(%) 8.82 8.71 4.93 0.87 4.32

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
16 Jul 2025 0.14 1.4 0 219.04
12 Jul 2024 0.11 1.1 0 150.45

Peers

Other companies within the same industry or sector that are comparable to Piramal Pharma Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 796.00 0.79 47.27 104.93 301.39 0.63
Lotus Eye Hospital and Institute Ltd 116.39 -0.51 375.45 382.34 3.55 0.00
Vaishali Pharma Ltd 7.47 0.13 0.00 2398.55 3.13 0.00
Astec Lifesciences Ltd 710.70 -0.64 0.00 360.56 -363.15 0.00

Company Info

Our Company was incorporated on March 4, 2020 at Mumbai as a public limited company under the Companies Act and was granted the certificate of incorporation by the RoC.Major events and milestones:2020-Acquired pharmaceutical business from PEL-20% Strategic Growth Investment by Carlyle-Increased stake to 100% in CCPL2021Acquisition of HPPL2022-Acquisition of minority stake in Yapan Bio Private Limited-Composite Scheme of Arrangement under the provisions of section 230 to 232 and other applicable provisions of the Companies Act, 2013 amongst PEL, the Company, CCPL, HPPL, PFPL and their respective shareholders and creditors, sanctioned by the NCLT on August 12, 2022. Pursuant to the Scheme, Demerged Undertaking of PEL, transferred and vested into the Company. 2020 -Piramal Pharma and Navin Fluorine Mutually Agree on Piramal Increasing its Stake to 100% in Convergence Chemicals. -Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs. -Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish -Piramal Critical Care Announces Strategic Partnership with US-Based Pharmaceutical Outsourcing Facility Medivant Healthcare 2021 -Piramal Pharma Solutions Announces Winner of its Inaugural Award for Excellence in Patient Centricity. -Piramal Pharma Solutions Enters Into a Master Services Agreement with Plus Therapeutics, Inc. -Piramal Pharma Limited's Consumer Products Division Launches `i-feelr' 2022 -Piramal Pharma Solutions Announces Winner of its September 2022 Award for Excellence in Patient Centricity. -Piramal Pharma Solutions Launches ADCelerate, a Rapid, Integrated Approach to Taking ADCs to IND. -Piramal Pharma Solutions Holds Grand Opening Ceremony for New API Plant at Aurora, Canada Manufacturing Site. -Piramal Pharma Solutions New API Plant in Canada Goes Online; Initial Production Runs Successfully Completed. 2023 -Company issued rights shares of Rs. 10 in the ratio of 5:46 at a premium of Rs. 71 per share. 2024 - Piramal Pharma Limited (PPL) launches new campaign for Polycrol with Brand Ambassador Jisshu Sengupta. -Piramal Pharma Limited ( the Company ) forays into men's grooming market with the launch of BOHEM. 2025 -Piramal Critical Care Announces U.S. Launch of ChlorpromazineHydrochloride for Injection, USP.

Our Company was incorporated on March 4, 2020 at Mumbai as a public limited company under the Companies Act and was granted the certificate of incorporation by the RoC.Major events and milestones:2020-Acquired pharmaceutical business from PEL-20% Strategic Growth Investment by Carlyle-Increased stake to 100% in CCPL2021Acquisition of HPPL2022-Acquisition of minority stake in Yapan Bio Private Limited-Composite Scheme of Arrangement under the provisions of section 230 to 232 and other applicable provisions of the Companies Act, 2013 amongst PEL, the Company, CCPL, HPPL, PFPL and their respective shareholders and creditors, sanctioned by the NCLT on August 12, 2022. Pursuant to the Scheme, Demerged Undertaking of PEL, transferred and vested into the Company. 2020 -Piramal Pharma and Navin Fluorine Mutually Agree on Piramal Increasing its Stake to 100% in Convergence Chemicals. -Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs. -Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish -Piramal Critical Care Announces Strategic Partnership with US-Based Pharmaceutical Outsourcing Facility Medivant Healthcare 2021 -Piramal Pharma Solutions Announces Winner of its Inaugural Award for Excellence in Patient Centricity. -Piramal Pharma Solutions Enters Into a Master Services Agreement with Plus Therapeutics, Inc. -Piramal Pharma Limited's Consumer Products Division Launches `i-feelr' 2022 -Piramal Pharma Solutions Announces Winner of its September 2022 Award for Excellence in Patient Centricity. -Piramal Pharma Solutions Launches ADCelerate, a Rapid, Integrated Approach to Taking ADCs to IND. -Piramal Pharma Solutions Holds Grand Opening Ceremony for New API Plant at Aurora, Canada Manufacturing Site. -Piramal Pharma Solutions New API Plant in Canada Goes Online; Initial Production Runs Successfully Completed. 2023 -Company issued rights shares of Rs. 10 in the ratio of 5:46 at a premium of Rs. 71 per share. 2024 - Piramal Pharma Limited (PPL) launches new campaign for Polycrol with Brand Ambassador Jisshu Sengupta. -Piramal Pharma Limited ( the Company ) forays into men's grooming market with the launch of BOHEM. 2025 -Piramal Critical Care Announces U.S. Launch of ChlorpromazineHydrochloride for Injection, USP.

Read More

Parent Organisation

Piramal Pharma Ltd.

Founded

04/03/2020

Managing Director

NSE Symbol

PPLPHARMAEQ

FAQ

The current price of Piramal Pharma Ltd is ₹ 179.85.

The 52-week high for Piramal Pharma Ltd is ₹ 185.47 and the 52-week low is ₹ 178.30.

The market capitalization of Piramal Pharma Ltd is currently ₹ 23906.53. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Piramal Pharma Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Piramal Pharma Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Piramal Pharma Ltd shares.

The CEO of Piramal Pharma Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT